Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Final Analysis of a Lysa Multicenter, Phase II Study. "the TOTAL Trial"

被引：2

作者：

Tournilhac, Olivier ^{[1
]}

Lecolant, Solene ^{[2
]}

Hacini, Maya ^{[3
]}

Bouabdallah, Krimo ^{[4
]}

Bailly, Sebastien ^{[5
]}

Laribi, Kamel ^{[6
]}

Belmondo, Thibaut ^{[7
,8
,9
]}

Maerevoet, Marie ^{[10
]}

Ysebaert, Loic ^{[11
]}

Guidez, Stephanie ^{[12
]}

Le Gouill, Steven ^{[13
]}

Bonnet, Christophe ^{[14
]}

Andre, Marc ^{[15
]}

Dupuis, Jehan ^{[16
]}

Thieblemont, Catherine ^{[17
]}

Bachy, Emmanuel ^{[18
]}

Daguindau, Nicolas ^{[19
]}

Morschhauser, Franck ^{[20
,21
,22
]}

Tricot, Sabine ^{[23
]}

Feugier, Pierre ^{[24
]}

Banos, Anne ^{[25
]}

Lamy, Thierry ^{[26
]}

Chauchet, Adrien ^{[27
]}

Gyan, Emmanuel ^{[28
]}

Cartron, Guillaume ^{[29
]}

Farhat, Hassan ^{[30
]}

Camus, Vincent ^{[31
]}

Drenou, Bernard ^{[32
]}

Zerazhi, Hacene ^{[33
]}

Sibon, David ^{[34
]}

Nicolas-Virelizier, Emmanuelle ^{[35
]}

Delette, Caroline ^{[36
]}

Snauwaert, Sylvia ^{[37
]}

Straetmans, Nicole ^{[38
]}

Delarue, Richard ^{[39
]}

Parrens, Marie ^{[40
]}

Griolet, Samuel ^{[41
]}

Gaulard, Philippe ^{[42
]}

Delfau-Larue, Marie-Helene ^{[43
]}

De Leval, Laurence ^{[44
,45
]}

Damaj, Gandhi Laurent ^{[46
]}

机构：

[1] Univ Clermont Auvergne, CHU, Serv Hematol Clin & Therapie Cellulaire, EA7453 Chelter CIC 1405, Clermont Ferrand, France

[2] Grp Hosp Henri Mondor, AP HP, Dept Biol Hematol & Immunol, Lab Immunol, Creteil, France

[3] Ctr Hosp Metropole Savoie, Hematol, Chambery, France

[4] CHU Bordeaux, Hematol & Cellular Therapy Dept, Pessac, France

[5] CHU Clermont Ferrand, Hematol & Therapie Cellulaire, Clermont Ferrand, France

[6] CH Le Mans, Hematol Clin, Le Mans, France

[7] Grp Hosp Henri Mondor, Dept Biol Hematol & Immunol, Creteil, France

[8] Grp Hosp Henri Mondor, Lab Immunol, Creteil, France

[9] Grp Hosp Henri Mondor, AP HP, Creteil, France

[10] ULB, Inst Jules Bordet, Hematol, Brussels, Belgium

[11] IUCT Oncopole, Toulouse, France

[12] CHU Poitiers, Serv Hematol & Therapie Cellulaire, CIC INSERM 1402, Poitiers, France

[13] Inst Curie Comprehens Canc Ctr, Paris, France

[14] CHU Univ Liege, Clin Hematol, Liege, Belgium

[15] Catholic Univ Louvain, Dept Hematol, CHU UCL Namur, Yvoir, Belgium

[16] Henri Mondor Univ Hosp, Lymphoid Malignancies Dept, Creteil, France

[17] Univ Paris Cite, St Louis Univ Hosp, AP HP, Hematooncol Dept, Paris, France

[18] Lyon Sud Univ Hosp, Hosp Civils Lyon, Dept Hematol, Pierre Benite, France

[19] CH Annecy Genevois, Hematol Dept, Annecy, France

[20] CHU Lille, Serv Malad Sang, F-59000 Lille, France

[21] Univ Lille 2, Ctr Hosp Reg Univ CHRU Lille, Dept Clin Hematol, Lille, France

[22] Univ Lille 2, Unite Grp Rech Formes Injetables & Technol Associ, Lille, France

[23] CH Valenciennes, Serv Hematol Clin, Valenciennes, France

[24] Henri Poincare Univ, Dept Hematol, CHU NANCY BRABOIS, Vandoeuvre Les Nancy, France

[25] Ctr Hosp Bayonne, Serv Hematol, Bayonne, France

[26] CHU Rennes, Serv Hematol Clin, Rennes, France

[27] CHU Besancon, Hematol, Besancon, France

[28] CHU Tours, Serv Hematol & Therapie Cellulaire, Tours, France

[29] CHU Montpellier, Dept Hematol Clin, Montpellier, France

[30] Hop Andre Mignot, Dept Hematol, Ctr Hosp Versailles, Le Chesnay, France

[31] Ctr Henri Becquerel, Dept Clin Hematol, Rouen, France

[32] Grp Hosp Reg Mulhouse Sud Alsace GHRMSA, Serv Hematol, Mulhouse, France

[33] CH Avignon, Hematol, Avignon, France

[34] Paris Est Creteil Univ, Fac Med & Hlth, Campus Henri Mondor, Creteil, France

[35] Ctr Leon Berard, Hematol, Lyon, France

[36] CHU Amiens, Serv Hematol Clin & Therapie Cellulaire, Amiens, France

[37] Acad Hosp St Jan, Brugge, Belgium

[38] Clin Univ St Luc, Dept Hematol, Woluwe St Lambert, Belgium

[39] Necker Univ Hosp, AP HP, Hematol Dept, Hemophilia Ctr, Paris, France

[40] Univ Bordeaux, Dept Pathol, Bordeaux, France

[41] Ctr Hosp Lyon Sud, Lymphoma Acad Res Org LYSARC, Lyon, France

[42] Henri Mondor Hosp, AP HP, Paris Est Creteil UPEC Univ Fac, Dept Pathol,INSERM UMR S 955, Creteil, France

[43] CHU Henri Mondor, AP HP, Biol Hematol & Immunol Dept, Creteil, France

[44] Lausanne Univ Hosp, Dept Lab Med & Pathol, Inst Pathol, Lausanne, Switzerland

[45] Lausanne Univ, Lausanne, Switzerland

[46] Univ Hosp Sch Med, Dept Hematol, Hematol Inst, Caen, France

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-165217

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2302 / 2305

页数：4

共 50 条

[21] Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis
Sano, Dahlia
Liu, Nicholas
Knowles, Scott
MacEwan, Joanna P.
Wang, Shu
Wogen, Jenifer
Yu, Kristina S.
Lee, Seung Tae
CURRENT ONCOLOGY, 2024, 31 (05) : 2598 - 2609
[22] Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study
Stamatoullas, Aspasia
Ghesquieres, Herve
Feugier, Pierre
Andre, Marc
Le Bras, Fabien
Gac, Anne-Claire
Borel, Cecile
Gastinne, Thomas
Quittet, Philippe
Morschhauser, Franck
Ribrag, Vincent
Guidez, Stephanie
Nicolas-Virelizier, Emmanuelle
Berriolo-Riedinger, Alina
Vander Borght, Thierry
Edeline, Veronique
Brice, Pauline
LEUKEMIA & LYMPHOMA, 2022, 63 (13) : 3063 - 3071
[23] Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study
Bhurani, Mansi
Admojo, Lorenz
Van der Weyden, Carrie
Twigger, Robert
Bazargan, Ali
Quach, Hang
Zimet, Allan
Coyle, Luke
Lindsay, Julian
Radeski, Dejan
Hawkes, Eliza
Kennedy, Glen
Irving, Ian
Gutta, Naadir
Trotman, Judith
Yeung, James
Dunlop, Lindsay
Hua, Minh
Giri, Pratyush
Yuen, Sam
Panicker, Shyam
Moreton, Susan
Khoo, Liane
Scott, Ashleigh
Kipp, David
McQuillan, Andrew
McCormack, Chris
Dickinson, Michael
Prince, Henry Miles
LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 330 - 336
[24] Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
Duvic, Madeleine
Tetzlaff, Michael T.
Gangar, Pamela
Clos, Audra L.
Sui, Dawen
Talpur, Rakhshandra
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3759 - +
[25] Brentuximab Vedotin in refractory or relapsed Peripheral T-cell Lymphoma: The French name patient program experience in 66 patients
Lamarque, Mathilde
Contejean, Adrien
Bossard, Celine
Fournier, Marion
Brice, Pauline
Delarue, Richard
Gaulard, Philippe
Haioun, Corinne
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S221 - S222
[26] A Phase I Trial of Brentuximab Vedotin in Combination with Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Ward, Jeffrey P.
Thein, Jessica
Luo, Jingqin
Wagner-Johnston, Nina D.
Cashen, Amanda F.
Fehniger, Todd A.
Bartlett, Nancy L.
BLOOD, 2015, 126 (23)
[27] BRENTUXIMAB VEDOTIN IN REFRACTORY OR RELAPSED PERIPHERAL T-CELL LYMPHOMA: THE FRENCH NAME PATIENT PROGRAM EXPERIENCE IN 65 PATIENTS
Mathilde, L.
Contejean, A.
Bossard, C.
Parrens, M.
Fournier, M.
Pallardy, S.
Morschhauser, F.
Bouabdallah, R.
Salles, G.
Tilly, H.
Brice, P.
Delarue, R.
Haioun, C.
Gaulard, P.
HAEMATOLOGICA, 2014, 99 : 151 - 152
[28] PHASE II STUDY OF SMILE CHEMOTHERAPY FOR RELAPSED/ REFRACTORY PERIPHERAL T-CELL LYMPHOMA
Suzuki, R.
Hyo, R.
Kim, W. S.
Tsukamoto, N.
Maeda, Y.
Masaki, Y.
Sakai, R.
Masunari, T.
Niitsu, N.
Ishida, F.
Nakamura, S.
Suzumiya, J.
HAEMATOLOGICA, 2015, 100 : 401 - 401
[29] A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
Bennani, N. Nora
Pederson, Levi D.
Atherton, Pamela
Micallef, Ivana
Colgan, Joseph P.
Thanarajasingam, Gita
Nowakowski, Grzegorz
Witzig, Thomas E.
Feldman, Andrew L.
Ansell, Stephen M.
BLOOD, 2019, 134
[30] Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial
William, Basem M.
Huang, Ying
Johnson, Amy
Brammer, Jonathan E.
Reneau, John C.
Maakaron, Joseph
Larbi, Ruth
Grantier, Cara
Hoffman, Corinne
Ayyappan, Sabarish
Baiocchi, Robert A.
Epperla, Narendranath
Christian, Beth A.
Alinari, Lapo
Maddocks, Kami J.
Chung, Catherine
BLOOD, 2019, 134

← 1 2 3 4 5 →